Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

23.00 +1.12 (+5.14%)
Streaming Delayed Price Updated: 1:49 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble ↗
The SEC is calling out a several stocks for non-compliance. Could they face delisting? 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
During Thursday, 166 stocks hit new 52-week lows. 52-Week Low Highlights: Alibaba Group Holding (NYSE:BABA) was the largest firm on a market cap basis to set a new 52-week... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Innate Pharma (NASDAQ:IPHA) stock increased by 13.7% to $3.32 during Thursday's pre-market session. The market value of their outstanding shares is at $264.6... 
Via Benzinga
News headline image
Recap: Zai Lab FY Earnings ↗
Zai Lab (NASDAQ:ZLAB) reported its FY earnings results on Tuesday, March 1, 2022 at 04:30 PM. Here's what investors need to know about the announcement. Earnings Zai Lab... 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2022 ↗
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a... 
Via Benzinga
News headline image
Zai Lab Revenue Triples, As It Struggles To Break Cycle Of Mounting Losses ↗
Key takeaways: Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing The company hopes heavy R&D... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Tonix Pharmaceuticals (NASDAQ:TNXP) stock rose 49.1% to $0.28 during Thursday's regular session. As of 12:31 EST, Tonix Pharmaceuticals's stock is trading... 
Via Benzinga
News headline image
63 Biggest Movers From Yesterday ↗
Gainers Indonesia Energy Corporation Limited (NASDAQ: INDO) shares climbed 39.3% to close at $20.20 on Thursday after jumping around 35% on Wednesday. DBV Technologies S.A. (... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Trevi Therapeutics (NASDAQ:TRVI) shares rose 46.6% to $1.28 during Wednesday's regular session. As of 12:30 EST, Trevi Therapeutics's stock is trading at a... 
Via Benzinga
News headline image
41 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported... 
Via Benzinga
News headline image
A Preview Of Zai Lab's Earnings ↗
Zai Lab (NASDAQ:ZLAB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More ↗
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that... 
Via Talk Markets
News headline image
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the... 
Via Benzinga
Promising Developments in Breast Cancer Treatments Ahead in 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 12, 2022 – USA News Group – So far in 2022, there have already been some impressive developments in the battle against... 
Via FinancialNewsMedia
News headline image
Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease ↗
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart (efgartigimod alfa-fcab) for generalized myasthenia gravis (gMG) in adult patients who are anti-... 
Via Benzinga
News headline image
Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board ↗
BeiGene, a Beijing oncology company, began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong, and Shanghai. 
Via Talk Markets
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Down 2.5%; Calliditas Therapeutics Shares Spike Higher ↗
Toward the end of trading Thursday, the Dow traded up 0.05% to 35,946.32 while the NASDAQ fell 2.5% to 15,179.38. The S&P also fell, dropping 0.80% to 4,672.38. The U.S. has... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Calliditas Therapeutics (NASDAQ:CALT... 
Via Benzinga
News headline image
31 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Calliditas Therapeutics AB (NASDAQ: CALT) shares climbed 28.7% to $24.13 after the company announced it was granted by the FDA accelerated approval of TARPEYO to reduce... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
News headline image
Zai Lab's Nuzyra Approved In China For Bacterial Infections ↗
The China National Medical Products Administration (NMPA) has approved Zai Lab Limited's (NASDAQ: ZLAB) Nuzyra (omadacycline), a novel antibiotic with both oral... 
Via Benzinga
News headline image
46 Biggest Movers From Yesterday ↗
Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday. CMC Materials, Inc. (NASDAQ: CCMP) climbed 33.9% to close at $195.50 on... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Biofrontera (NASDAQ: 
Via Benzinga
News headline image
36 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates ↗
Following the market opening Wednesday, the Dow traded down 0.26% to 35,453.17 while the NASDAQ fell 0.62% to 15,142.70. The S&P also fell, dropping 0.28% to 4,621.34. The U.S... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
News headline image
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million ↗
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics. 
Via Talk Markets
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.